BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 11, 2025
Home » Newsletters » BioWorld

BioWorld

Aug. 30, 2024

View Archived Issues
Generic injection pens

Private labels, slow uptake mark first year of Humira biosimilars

Although last year’s massive U.S. launch of Humira biosimilars captured headlines, the market adoption of those competitors has been nothing to write home about, even with discounts as low as 85% off the innovator price. Read More

Learning curve: Alnylam vutrisiran phase III sparks data debates

Potential implications for others in the space, including Pfizer Inc. and Bridgebio Pharma Inc., became the subject of buzz after Alnylam Pharmaceuticals Inc. provided details from the Helios-B phase III study with RNAi candidate vutrisiran, in the works for ATTR amyloidosis with cardiomyopathy.

Read More
Brain activity concept illustration

Despite clinical failure, new analysis supports Actinogen's Xanamem

After initially reporting that Xanamem failed to meet the primary endpoint in cognitive attention in the phase IIa Xanacidd cognition and depression trial, Actinogen Medical Ltd. CEO Steven Gourlay said a new analysis shows clinically and statistically significant benefits in depression. Read More
Nonprofit stamp

Biopharma grants reach four-year high of $2.5B; nonprofit deals down

Through July 2024, biopharma firms received $2.52 billion in grants, marking a 52% increase from $1.66 billion in grants during the same period last year. However, nonprofit deals are at their lowest level on record, according to BioWorld’s records. Although nonprofit deal values were initially higher in April compared to 2023, they have since dropped and are now well below the levels seen in prior years. Read More
RD.png

AI-based Noetik closes on an oversubscribed $40M series A

Artificial intelligence (AI) drug discovery company Noetik Inc. has closed on an oversubscribed $40 million series A financing round. The company plans to use the money to expand its atlas of human cancer biology with its in vivo CRISPR platform to advance a pipeline of cancer therapeutics to the clinic. In describing its approach, the company said that making a genuine impact on drug discovery requires computational capabilities to understand and simulate disease biology at the patient level, identifying the right targets and matching them with the right therapies. Read More

Holiday notice

BioWorld's offices will be closed in observance of Labor Day in the U.S. No issue will be published Monday, Sept. 2. Read More

Money raised by biopharma

Total raised in public, private and other financings of biopharma companies, comparing 2019-2024. Read More

Biopharma money raised: Jan. 1-Aug. 29, 2024

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Appointments and advancements for Aug. 30, 2024

New hires and promotions in the biopharma industry, including: Hookipa, Ventyx. Read More

Financings for Aug. 30, 2024

Biopharmas raising money in public or private financings, including:  Aprinoia, Avicanna, Betterlife, Geovax Labs, TC Biopharm. Read More

In the clinic for Aug. 30, 2024

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Gain Therapeutics, Merck. Read More

Other news to note for Aug. 30, 2024

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biocon Biologics, Biomarin, Janssen, Johnson & Johnson, Repare. Read More

Regulatory actions for Aug. 30, 2024

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: GSK, Janssen, Nuvectis, Scilex. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing